TY - JOUR
T1 - Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma
AU - Jung, Jongheon
AU - Heo, Ja Yoon
AU - Lee, Eunyoung
AU - Lee, Hyewon
AU - Chang, Myung Hee
AU - Park, Ju Hyun
AU - Eom, Hyeon Seok
N1 - Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2023/2
Y1 - 2023/2
N2 - Purpose: Peripheral T-cell lymphoma (PTCL) is an aggressive and heterogenous T-cell lymphoid malignancy. The prognostic value of C-reactive protein-to-albumin ratio (CAR) has never been assessed in PTCL. Materials and methods: This study retrospectively reviewed the medical records of 76 patients diagnosed with various subtypes of PTCL. A CAR cutoff value of 0.794 was determined, and clinical outcomes, including response rate, overall survival (OS), and progression-free survival (PFS), were compared between the high (> 0.794) and low (≤ 0.794) CAR groups. Results: After induction therapy, complete response was achieved in 8 (32.0%) and 39 patients (76.5%) in the high and low CAR groups, respectively. During the median follow-up of 57.5 months, the high CAR group had significantly worse 5-year PFS and 5-year OS rates. Even with adjustment for the International Prognostic Index (≥ 3), Prognostic Index for PTCL-unspecified (≥ 3), and T cell score (≥ 2), high CAR remained a significant prognostic factor for PFS (hazard ratio [HR]: 4.01, 95% confidence interval [CI] 2.04–7.86, p < 0.001) and OS (HR: 2.97, 95% CI: 1.33–6.64, p = 0.008). Conclusion: CAR may play a complementary role in predicting prognosis in patients with PTCL, considering its simplicity, objectivity, and easy accessibility.
AB - Purpose: Peripheral T-cell lymphoma (PTCL) is an aggressive and heterogenous T-cell lymphoid malignancy. The prognostic value of C-reactive protein-to-albumin ratio (CAR) has never been assessed in PTCL. Materials and methods: This study retrospectively reviewed the medical records of 76 patients diagnosed with various subtypes of PTCL. A CAR cutoff value of 0.794 was determined, and clinical outcomes, including response rate, overall survival (OS), and progression-free survival (PFS), were compared between the high (> 0.794) and low (≤ 0.794) CAR groups. Results: After induction therapy, complete response was achieved in 8 (32.0%) and 39 patients (76.5%) in the high and low CAR groups, respectively. During the median follow-up of 57.5 months, the high CAR group had significantly worse 5-year PFS and 5-year OS rates. Even with adjustment for the International Prognostic Index (≥ 3), Prognostic Index for PTCL-unspecified (≥ 3), and T cell score (≥ 2), high CAR remained a significant prognostic factor for PFS (hazard ratio [HR]: 4.01, 95% confidence interval [CI] 2.04–7.86, p < 0.001) and OS (HR: 2.97, 95% CI: 1.33–6.64, p = 0.008). Conclusion: CAR may play a complementary role in predicting prognosis in patients with PTCL, considering its simplicity, objectivity, and easy accessibility.
KW - C-reactive protein
KW - Lymphoma
KW - Peripheral
KW - Prognosis
KW - T cell
UR - http://www.scopus.com/inward/record.url?scp=85144038070&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03474-x
DO - 10.1007/s12185-022-03474-x
M3 - Article
C2 - 36520352
AN - SCOPUS:85144038070
SN - 0925-5710
VL - 117
SP - 216
EP - 224
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 2
ER -